Dr. Matt Might
Dr. Matthew Might is an Associate Professor in the School of Computing at the University of Utah, where he works on cybersecurity, scientific computing and foundational research in programming languages. He has received a CAREER Award from the National Science Foundation, and in 2014, he was appointed one of six Presidential Scholars at the University of Utah. Might received his Ph.D. in Computer Science from Georgia Tech. His son, Bertrand, was the first patient ever discovered with a rare disorder known as N-Glycanase deficiency. Matt posted an essay online that catalyzed the creation of a patient community, the remarkable aftermath of which has been chronicled in publications such as The New Yorker and Der Spiegel.
Dr. Slavé Petrovski
Dr. Slavé Petrovski received his PhD from the University of Melbourne, Australia and has a combined Bachelor of Information Systems and Bachelor of Science (Honors). He is the recipient of multiple awards and grants, and is listed as an inventor on a medical genomics diagnostic patent. He is currently a computational geneticist at the University of Melbourne. Slavé is the recipient of the National Health and Medical Research Council's CJ Martin Overseas Fellowship. This has facilitated the opportunity to work at highly respected international universities, including the Center for Human Genome Variation, Duke University, North Carolina, Imperial College London and Columbia University, New York.
Mark W. Flynn is Co-Managing Partner of GSV Asset Management and the President of GSV Capital, a publicly traded fund focused on identifying and investing in rapidly growing late stage venture capital-backed private companies. Previously, Mark managed Trilogy Capital Partners, a Menlo Park California based private investment and consulting firm, since its formation in 1997. Prior to forming Trilogy, he worked in various capacities in the investment banking groups at Salomon Brothers and Volpe, Brown & Whelan. Mark has served as chairman of The Preserve Company, as a member of the board of directors of the DAPER Fund at Stanford University as well as a number of privately held companies. He holds an M.B.A. from Harvard Business School, is a C.P.A., and received his B.A. from Saint John's University in Collegeville, Minnesota.
Gray Knowlton is the Chief Information Officer of Upsher-Smith Laboratories. Gray has been producing technology solutions since 1995, beginning with desktop publishing, extending through large-scale publishing automation systems. His experience includes 15 years with Adobe and Microsoft, leading areas of Adobe Acrobat, Microsoft Office and other world-leading products. By working with leading industry groups like the Bill & Melinda Gates Foundation, DAISY Consortium, Epilepsy Foundation of America, the Brian Grant Foundation and others, Gray has contributed valuable technology and expertise in support of improving lives for those in need. Gray Knowlton lives in Minneapolis, MN with his family.
Dr. Steven Petrou
Professor Petrou is a Deputy Director and co-Head of the Division of Epilepsy at the Florey Institute of Neuroscience and Mental Health. He leads the Laboratory of Ion Channels and Human Disease, a multidisciplinary team of researchers with a focus on revealing fundamental mechanisms of disease genesis in the central nervous system. Current major areas of investigation center on the development and characterization of genetically engineered mice models for the study of human familial epilepsy. He also serves on numerous boards including the Editorial board of the Journal Neurobiology of Disease, is an Associate Editor at PLOS Genetics, and is a member of the Genetics Commission of the International League Against Epilepsy. Steven received his BSc(Hons) and PhD from the University of Melbourne.
Dr. Orrin Devinsky
Dr. Orrin Devinsky is the Director of the NYU Comprehensive Epilepsy Center and the Saint Barnabas Institute of Neurology and Neurosurgery (INN). He is also a Professor of Neurology, Neurosurgery and Psychiatry at NYU Langone School of Medicine. Orrin specializes in epilepsy and behavioral neurology. He received his B.S. and M.S. from Yale University and his M.D. from Harvard Medical School.
Dr. David Goldstein
Founding Scientist &Chair of the Advisory Board
Dr. David Goldstein serves as Professor of Genetics and Development in the College of Physicians and Surgeons and Director of the Institute for Genomic Medicine at Columbia University (NY). He is an investigator and key advisor for CURE’s Epilepsy Genetics Initiative, a groundbreaking project dedicated to advancing epilepsy genetics. David is also a member of Epi4K, an international consortium of doctors, scientists and researchers working together to further our understanding of the genetic basis of epilepsy. He received his PhD in Biological Sciences from Stanford University.